Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHRENILIN vs AXOTAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PHRENILIN is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation. Acetaminophen inhibits cyclooxygenase (COX) in the CNS, reducing prostaglandin synthesis. Caffeine is a nonselective adenosine receptor antagonist, promoting vasoconstriction and enhancing analgesic effects.
Axotal contains butalbital, a barbiturate that enhances GABA-A receptor activity, and acetaminophen, an analgesic and antipyretic whose mechanism is not fully understood but may involve COX inhibition and activation of descending serotonergic pathways.
Tension headache
Tension headache
For tension headache: 1-2 capsules (each containing butalbital 50 mg, acetaminophen 300 mg, and caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.
Each tablet: butalbital 50 mg, acetaminophen 300-500 mg, caffeine 40 mg. 1-2 tablets orally every 4 hours as needed, not exceeding 6 tablets per day.
Butalbital: terminal half-life ~35 hours (range 20-50 h); acetaminophen: ~2-3 hours (prolonged in hepatic impairment); caffeine: ~3-6 hours.
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged to 8-12 hours in severe renal impairment (Cr Cl <30 m L/min).
Butalbital is extensively metabolized by hepatic CYP450 enzymes (especially CYP2C9) and excreted in urine. Acetaminophen is primarily conjugated in the liver via glucuronidation and sulfation, with minor CYP2E1-mediated metabolism to a toxic metabolite (NAPQI). Caffeine is metabolized predominantly by CYP1A2.
Butalbital is metabolized primarily by CYP2C19; acetaminophen is metabolized mainly via glucuronidation by UGT1A1 and UGT1A6, sulfation by SULT1A1, and minor oxidation by CYP2E1.
PHRENILIN (butalbital/acetaminophen/caffeine): Renal excretion of metabolites; butalbital ~60-70% unchanged in urine, acetaminophen ~2-4% unchanged with majority as glucuronide and sulfate conjugates, caffeine metabolites primarily renal.
Renal excretion of unchanged drug (60-70%) and glucuronide conjugates (10-20%); biliary excretion (5-10%); fecal elimination (<10%).
Butalbital: ~45% bound to plasma proteins; acetaminophen: 10-25% bound; caffeine: ~35% bound.
98-99% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Butalbital: Vd ~0.8 L/kg; acetaminophen: Vd ~0.9 L/kg; caffeine: Vd ~0.6 L/kg. Overall Vd for combination not established; butalbital widely distributed.
0.15-0.25 L/kg, indicating distribution mainly in extracellular fluid and limited tissue penetration.
Oral: butalbital ~90% (complete absorption); acetaminophen ~85-90%; caffeine ~100%.
Oral: 85-95%; intramuscular: 90-100%; intravenous: 100%.
GFR 30-50 m L/min: Use with caution, maximum 4 capsules per day. GFR <30 m L/min: Avoid use due to accumulation of acetaminophen metabolites and butalbital. Not recommended in dialysis.
No specific guidelines; contraindicated in severe renal impairment (Cr Cl <30 m L/min). Use with caution in mild-moderate impairment due to acetaminophen and butalbital accumulation.
Child-Pugh A: Use with caution, maximum 4 capsules per day. Child-Pugh B or C: Contraindicated due to impaired metabolism of butalbital and hepatotoxicity risk from acetaminophen.
Contraindicated in Child-Pugh Class C (severe hepatic impairment). In Child-Pugh A or B, reduce dose or extend interval; maximum acetaminophen 2000 mg/day, avoid butalbital if possible.
Not recommended in children under 12 years of age due to butalbital and caffeine content. For adolescents 12-17 years: 1 capsule orally every 4 hours as needed, not exceeding 3 capsules per day.
Not recommended for children under 12 years. For ages 12-18: same as adult dose (1-2 tablets) but limit to 4 tablets per day and monitor for sedation.
Initiate at 1 capsule orally every 4 hours as needed, not exceeding 4 capsules per day. Monitor for sedation, cognitive impairment, and falls. Avoid in patients with severe hepatic or renal impairment.
Start at lower dose (1 tablet every 6 hours) due to increased sensitivity to butalbital (c NS depression, falls) and acetaminophen hepatotoxicity risk; limit to 4 tablets per day, avoid in frail elderly.
Barbiturates (butalbital) are habit-forming and may produce drug dependence. Withdrawal symptoms (e.g., anxiety, insomnia, seizures) can occur if abruptly discontinued. Use with caution in patients with a history of substance abuse.
Acetaminophen has been associated with cases of acute liver failure, sometimes resulting in liver transplant and death. Hepatotoxicity is usually associated with doses exceeding 4000 mg per day and often involves more than one acetaminophen-containing product.
Hepatotoxicity (acetaminophen) with overdose or chronic use; risk of dependence and withdrawal with butalbital; potential for caffeine-related effects (insomnia, palpitations); caution in patients with liver disease, renal impairment, or history of substance abuse.
Hepatotoxicity with acetaminophen overdose; risk of rhabdomyolysis, angioedema, Stevens-Johnson syndrome; butalbital dependence and withdrawal; CNS depression; impairment of mental or physical abilities; avoid concurrent alcohol use.
Hypersensitivity to any component; porphyria (butalbital); severe hepatic impairment (acetaminophen); concurrent use of MAOIs or other CNS depressants may potentiate effects.
Hypersensitivity to barbiturates or acetaminophen; porphyria; severe hepatic impairment; respiratory depression; history of substance abuse.
Avoid or limit caffeine-containing foods and beverages (coffee, tea, cola, chocolate) due to additive caffeine content. Alcohol should be strictly avoided due to enhanced CNS depression and hepatotoxicity risk. Grapefruit juice may affect caffeine metabolism; monitor for increased caffeine effects.
Avoid alcohol intake; concurrent use increases risk of acetaminophen hepatotoxicity. Grapefruit juice may increase caffeine levels; limit consumption. High-fat meals may delay absorption of butalbital. Maintain adequate hydration; caffeine has mild diuretic effect.
Butalbital: First trimester: Risk of major malformations (OR 1.4-2.0) including oral clefts; increased risk with prolonged use. Second and third trimesters: Avoid chronic use due to risk of neonatal withdrawal syndrome and hemorrhagic disease of newborn due to vitamin K deficiency. Acetaminophen: Considered low risk; no consistent evidence of teratogenicity. Caffeine: No increased risk of major malformations at moderate intake (<200 mg/day); high doses may be associated with growth restriction.
Pregnancy Category D. First trimester: Risk of cardiovascular malformations (e.g., Ebstein anomaly), neural tube defects, and oral clefts increased with lithium exposure. Second and third trimesters: Increased risk of fetal/neonatal toxicity including cardiac arrhythmias, hypoglycemia, polyhydramnios, preterm birth, and neonatal goiter. Avoid if possible; weigh risks vs. benefits.
Butalbital: Excreted into breast milk; M/P ratio unknown. Monitor infant for sedation, poor feeding, or withdrawal symptoms. Acetaminophen: Excreted in low amounts; M/P ratio approximately 1.0; considered compatible. Caffeine: Excreted in milk; M/P ratio 0.5-0.8; moderate intake likely safe; excessive use may cause irritability in infant.
Lithium is excreted into human milk (M/P ratio 0.3-0.8). Breastfeeding is not recommended due to risk of neonatal toxicity (hypotonia, hypothermia, cyanosis, ECG changes). Monitor infant serum levels if breastfeeding is continued.
No specific dose adjustments for butalbital or acetaminophen based on pregnancy pharmacokinetics. However, avoid prolonged use or high doses. For caffeine, limit to <200 mg/day. Use lowest effective dose for shortest duration. Monitor for signs of butalbital accumulation in pregnancy due to increased volume of distribution; no formal recommendation for dose reduction.
Dose adjustments are often necessary due to increased glomerular filtration rate and expanded plasma volume. Monitor serum levels closely (every 2-4 weeks in second and third trimesters). Dose may need to be increased or given in divided doses (e.g., 3 times daily) due to faster clearance. Postpartum: reduce dose promptly to pre-pregnancy levels within 24 hours after delivery to avoid toxicity from narrowed volume of distribution.
Phrenilin is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate; use with caution in patients with history of substance abuse or depression. Acetaminophen hepatotoxicity risk increases with doses >4g/day or in alcohol use disorder. Caffeine may exacerbate anxiety, insomnia, or tachyarrhythmias. Monitor for sedation and respiratory depression when used with other CNS depressants. Avoid abrupt discontinuation to prevent withdrawal symptoms.
AXOTAL (butalbital/acetaminophen/caffeine) is a combination analgesic for tension-type headaches. Butalbital is a barbiturate with addiction potential; limit use to less than 2 days per week to avoid medication overuse headache (MOH). Acetaminophen hepatic toxicity risk increases with chronic alcohol use or pre-existing liver disease. Caffeine may cause withdrawal headaches upon abrupt cessation.
Take only as prescribed; do not exceed recommended dose to avoid liver damage or addiction.,Avoid alcohol while taking this medication due to increased risk of liver toxicity and sedation.,Do not drive or operate heavy machinery until you know how this medication affects you.,If you have a history of substance abuse, inform your doctor before taking this medication.,Common side effects include drowsiness, dizziness, and nausea. Report severe allergic reactions or signs of liver damage (yellowing skin/eyes, dark urine, abdominal pain).,Do not stop taking suddenly without consulting your doctor, as withdrawal symptoms may occur.,Keep out of reach of children; acetaminophen overdose can be fatal.
Do not exceed 4 tablets per day to avoid acetaminophen overdose (max 4000 mg/day).,Avoid alcohol while taking this medication due to risk of liver damage.,This drug can be habit-forming; use only as prescribed for headache attacks, not for prophylaxis.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how you react.,Discontinue and seek medical help if you experience signs of liver injury (jaundice, dark urine) or allergic reaction (rash, swelling).,Caffeine content may interfere with sleep or exacerbate anxiety; limit other caffeine sources.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHRENILIN vs AXOTAL, answered by our medical review team.
PHRENILIN is a Barbiturate/Analgesic Combination that works by PHRENILIN is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation. Acetaminophen inhibits cyclooxygenase (COX) in the CNS, reducing prostaglandin synthesis. Caffeine is a nonselective adenosine receptor antagonist, promoting vasoconstriction and enhancing analgesic effects.. AXOTAL is a Barbiturate Combination Analgesic that works by Axotal contains butalbital, a barbiturate that enhances GABA-A receptor activity, and acetaminophen, an analgesic and antipyretic whose mechanism is not fully understood but may involve COX inhibition and activation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHRENILIN and AXOTAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHRENILIN is: For tension headache: 1-2 capsules (each containing butalbital 50 mg, acetaminophen 300 mg, and caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.. The standard adult dose of AXOTAL is: Each tablet: butalbital 50 mg, acetaminophen 300-500 mg, caffeine 40 mg. 1-2 tablets orally every 4 hours as needed, not exceeding 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHRENILIN and AXOTAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHRENILIN is classified as Category C. Butalbital: First trimester: Risk of major malformations (OR 1.4-2.0) including oral clefts; increased risk with prolonged use. Second and third trimesters: Avoid chronic use due t. AXOTAL is classified as Category C. Pregnancy Category D. First trimester: Risk of cardiovascular malformations (e.g., Ebstein anomaly), neural tube defects, and oral clefts increased with lithium exposure. Second an. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.